Red cell isoimmunisation

Published on 09/03/2015 by admin

Filed under Obstetrics & Gynecology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1160 times

Chapter 31 Red cell isoimmunisation

Prevention of RhD isoimmunisation

The aim is to provide passive immunisation at times of risk of fetomaternal transfusion. If no prophylaxis is given, 1% of RhD-negative women will develop anti-D antibodies by the end of the first pregnancy and a further 3%–5% have detectable antibodies 6 months after delivery. About 90% of sensitisations can be prevented. 100 IU anti-D immunoglobulin is able to neutralise 2 mL fetal blood. This is given within 72 hours of fetomaternal transfusion for maximum effect. In an RhD-negative woman with no anti-D antibodies present, anti-D prophylaxis is indicated in the following cases:

Antenatal management of Rhesus isoimmunisation

Other red cell antibodies

There are about 700 red cell antibodies, but only a few cause severe haemolytic disease of the newborn. Many antibodies (A, P(I), Le(a), M, I) produce an immunoglobulin M (IgM) response only, which cannot cross the placenta, so they are of no significance in pregnancy. Some red cell antigens are poorly developed on fetal red cells, so antibodies (Lu(b), Y+(a)), even if IgG produced and crosses the placenta, have no adverse affect. Antibodies known to stimulate haemolytic disease of the newborn include:

In Western countries, these have a higher frequency than D alloimmunisation and may be due to unmatched blood transfusions.